Promising results for combined COVID and flu vaccine from Moderna

Moderna's phase 3 trial of a combined COVID and flu vaccine showed higher immune response in adults aged 50 to 64 and those 65 and older. The vaccine was well tolerated with common side effects like muscle aches. Combination vaccines reduce costs, storage needs, and increase vaccination uptake. Globally, 3-5 million severe flu cases and 650,000 deaths occur annually. Moderna aims to supply the vaccine in 2025 pending regulatory approval.